MacuMira Microcurrent Stimulation for Dark Adaptation in Dry Age-Related Macular Degeneration
NCT07917715, Not applicable, Not yet recruiting, Clarity Eye Institute
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | MacuMira Microcurrent Stimulation for Dark Adaptation in Dry Age-Related Macular Degeneration | ClinicalTrials.gov |
| NCT number | NCT07917715 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 50 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Clarity Eye Institute | ClinicalTrials.gov |
| Conditions | Age-Related Macular Degeneration (AMD) | ClinicalTrials.gov |
| Interventions | Transpalpebral microcurrent electrical stimulation | ClinicalTrials.gov |
| First posted | 2026-11-04 | ClinicalTrials.gov |
| Last updated | 2026-11-04 | ClinicalTrials.gov |
Registered outcomes 8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Rod Intercept Time (RIT) from Baseline to Month 1 | Average of two baseline assessments (Screening/Baseline and Treatment Day 1) to the single assessment at Month 1. | Change in RIT, measured using the AdaptDx Pro dark adaptation test, from the average of two baseline assessments to the single RIT assessment at Month 1. The two baseline measurements will be obtained at the Screening/Baseline visit and Treatment Day 1, prior to the first MacuMira treatment, and averaged to establish baseline RIT. Each eligible eye will be assessed separately. | ClinicalTrials.gov |
| Secondary | Change in Rod Intercept Time (RIT) from Baseline to Month 3 | Average of two baseline assessments (Screening/Baseline and Treatment Day 1) to the single assessment at Month 3. | Change in RIT, measured using the AdaptDx Pro dark adaptation test, from the average of two baseline assessments to the single RIT assessment at Month 3. Each eligible eye will be assessed separately. | ClinicalTrials.gov |
| Secondary | Change in Best-Corrected Visual Acuity (BCVA) | Baseline to the single assessment at Month 1 and the single assessment at Month 3. | Change in BCVA, measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, from baseline to Month 1 and Month 3. | ClinicalTrials.gov |
| Secondary | Change in Contrast Sensitivity | Baseline to the single assessment at Month 1 and the single assessment at Month 3. | Change in contrast sensitivity, measured using the Pelli-Robson chart, from baseline to Month 1 and Month 3. | ClinicalTrials.gov |
| Secondary | Change in Low Luminance Deficit (LLD) | Baseline to the single assessment at Month 1 and the single assessment at Month 3. | Change in LDD from baseline to the single assessment at Month 1 and the single assessment at Month 3. | ClinicalTrials.gov |
| Secondary | Change in Vision-Related Quality of Life | Baseline to the single assessment at Month 1 and the single assessment at Month 3. | Change in vision-related quality of life, measured using the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25), from baseline to the single assessment at Month 1 and the single assessment at Month 3. | ClinicalTrials.gov |
| Other | Retinal Anatomic Stability Assessed by Optical Coherence Tomography (OCT) | Baseline to the assessment at Month 1 and the assessment at Month 3. | Assessment of retinal anatomic stability using OCT, including changes in macular thickness and macular volume, from baseline to Month 1 and Month 3. | ClinicalTrials.gov |
| Other | Changes in Fundus Autofluorescence (FAF) | Baseline to the assessment at Month 1 and the assessment at Month 3. | Assessment of changes in retinal appearance using FAF imaging from baseline to Month 1 and Month 3. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)